Effects of Different Components of Buyang Huanwu Tang on the PPAR γ /LXR α /ABCA1 Pathway in Hypercholesterolemia Mouse Model
Open Access
- 1 January 2025
- journal article
- Published by Wiley in International Journal of Genomics
- Vol. 2025 (1) , 9595757
Abstract
The aim of this study is to compare the effects of different components of Buyang Huanwu Tang (BYHWT) on the peroxisome proliferator‐activated receptor γ (PPAR γ )/liver X receptor α (LXR α )/ATP‐binding cassette transporter A1 (ABCA1) pathway and its lipid‐lowering effects. This study shows that the BYHWT alcohol precipitation and 75% alcohol components can significantly reduce the serum levels of triglycerides (TGs), low‐density lipoprotein (LDL), cholesterol (CHO), and hepatic function damage indicators such as glutamic oxaloacetic transaminase (AST) and glutamic pyruvic transaminase (ALT) in hypercholesterolemia mouse model. After treatment, the presence of lipid droplets in liver cells was reduced, and the destruction of adipocytes was improved. The Western blot (WB) results showed that alcohol precipitation and 75% alcohol components can upregulate PPAR γ , ABCA1, and LXR α . The expression of these components indicates that PPAR γ upregulation can activate LXR α , thus regulating the expression of ABCA1, mediating CHO efflux, promoting reverse cholesterol transport (RCT), and regulating the downstream gene CYP7A1 to participate in bile acid synthesis and metabolism. In summary, the experimental results indicate that the BYHWT alcohol precipitation, 50% alcohol, and 75% alcohol components can modulate the PPAR γ /LXR α /ABCA1 pathway in hypercholesterolemia mouse model to promote CHO metabolism.Keywords
Funding Information
- Heilongjiang University of Chinese Medicine (2023yjscx027)
- National Natural Science Foundation of China (82274405)
- National Natural Science Foundation of China (82074326)
This publication has 34 references indexed in Scilit:
- Pharmacological modulation of cholesterol 7α-hydroxylase (CYP7A1) as a therapeutic strategy for hypercholesterolemiaBiochemical Pharmacology, 2023
- Research progress of PPARγ regulation of cholesterol and inflammation in Alzheimer's diseaseMetabolic Brain Disease, 2023
- Saikosaponins ameliorate hyperlipidemia in rats by enhancing hepatic lipid and cholesterol metabolismJournal of Ethnopharmacology, 2022
- Cholesterol homeostasis regulated by ABCA1 is critical for retinal ganglion cell survivalScience China Life Sciences, 2022
- Selenium and vitamin B6 cosupplementation improves dyslipidemia and fatty liver syndrome by SIRT1/SREBP-1c pathway in hyperlipidemic Sprague-Dawley rats induced by high-fat dietNutrition Research, 2022
- Amyloid beta increases ABCA1 and HMGCR protein expression, and cholesterol synthesis and accumulation in mice neurons and astrocytesBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2022
- The ABCA1-efferocytosis axis: A new strategy to protect against atherosclerosisClinica Chimica Acta, 2021
- PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance DatabaseDrug Safety, 2020
- Lipid-lowering, hepatoprotective, and atheroprotective effects of the mixture Hong-Qu and gypenosides in hyperlipidemia with NAFLD ratsJournal of the Chinese Medical Association, 2016
- Identification of drugs that interact with herbs in drug developmentDrug Discovery Today, 2007